Oral Salmon Calcitonin Status

• Novartis continues additional manufacturing, formulation, packaging work

• Advanced clinical studies approved by Novartis following in-depth data review

• Phase IIb studies scheduled for 2004

Previous slide

Next slide

Back to first slide

View graphic version